Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 609

1.

Cardiovascular and renal complications of type 2 diabetes in obesity: role of sympathetic nerve activity and insulin resistance.

Masuo K, Rakugi H, Ogihara T, Esler MD, Lambert GW.

Curr Diabetes Rev. 2010 Mar;6(2):58-67. Review.

PMID:
20034369
2.

The role of sympathetic nervous activity in renal injury and end-stage renal disease.

Masuo K, Lambert GW, Esler MD, Rakugi H, Ogihara T, Schlaich MP.

Hypertens Res. 2010 Jun;33(6):521-8. doi: 10.1038/hr.2010.35. Epub 2010 Mar 26. Review.

PMID:
20339374
3.

Sympathetic nervous system, diabetes, and hypertension.

Perin PC, Maule S, Quadri R.

Clin Exp Hypertens. 2001 Jan-Feb;23(1-2):45-55. Review.

PMID:
11270588
4.

[Insulin resistance and arterial hypertension].

Weidmann P, Müller-Wieland D, de Courten M, Krone W.

Herz. 1995 Feb;20(1):16-32. Review. German.

PMID:
7713473
5.
6.

Hypertension in obesity and NIDDM. Role of insulin and sympathetic nervous system.

Daly PA, Landsberg L.

Diabetes Care. 1991 Mar;14(3):240-8. Review.

PMID:
2044439
7.

Sympathetic nervous system and insulin resistance: from obesity to diabetes.

Esler M, Rumantir M, Wiesner G, Kaye D, Hastings J, Lambert G.

Am J Hypertens. 2001 Nov;14(11 Pt 2):304S-309S. Review.

PMID:
11721888
8.

Insulin resistance, hyperinsulinemia and hypertension.

Weidmann P, de Courten M, Böhlen L.

J Hypertens Suppl. 1993 Dec;11(5):S27-38. Review.

PMID:
8158379
9.

[Sympathetic nervous factors, pressure variability and organ damage in arterial hypertension].

Mancia G, Seravalle G, Grassi G.

Ann Ital Med Int. 1997 Oct-Dec;12(4):217-22. Review. Italian.

PMID:
9773576
10.

Hyperinsulinemia, insulin resistance, and hypertension.

Bönner G.

J Cardiovasc Pharmacol. 1994;24 Suppl 2:S39-49. Review.

PMID:
7898093
11.

Beta2-adrenoceptor polymorphisms relate to obesity through blunted leptin-mediated sympathetic activation.

Masuo K, Katsuya T, Kawaguchi H, Fu Y, Rakugi H, Ogihara T, Tuck ML.

Am J Hypertens. 2006 Oct;19(10):1084-91.

PMID:
17027833
12.

beta2- and beta3-Adrenoceptor polymorphisms relate to subsequent weight gain and blood pressure elevation in obese normotensive individuals.

Kawaguchi H, Masuo K, Katsuya T, Sugimoto K, Rakugi H, Ogihara T, Tuck ML.

Hypertens Res. 2006 Dec;29(12):951-9.

PMID:
17378367
13.

Sympathetic nervous system activation in essential hypertension, cardiac failure and psychosomatic heart disease.

Esler M, Kaye D.

J Cardiovasc Pharmacol. 2000;35(7 Suppl 4):S1-7. Review.

PMID:
11346214
14.

Beta2- and beta3-adrenergic receptor polymorphisms are related to the onset of weight gain and blood pressure elevation over 5 years.

Masuo K, Katsuya T, Fu Y, Rakugi H, Ogihara T, Tuck ML.

Circulation. 2005 Jun 28;111(25):3429-34. Epub 2005 Jun 13.

15.

Insulin resistance and hyperinsulinemia in hypertension.

Weidmann P, Böhlen L, de Courten M.

J Hypertens Suppl. 1995 Aug;13(2):S65-72. Review.

PMID:
8576790
16.
17.

[Arterial rigidity and cardiovascular vagosympathetic activity in normotensive and hypertensive obese patients and type 2 diabetics].

Brahimi M, Dabire H, Platon P, Hadj-Brahim F, Attali JR, Valensi P.

Arch Mal Coeur Vaiss. 2001 Aug;94(8):944-6. French.

PMID:
11575237
18.

The pathogenesis of hypertension in obese subjects.

Weidmann P, de Courten M, Boehlen L, Shaw S.

Drugs. 1993;46 Suppl 2:197-208; discussion 208-9. Review.

PMID:
7512475
19.

Insulin and insulin resistance: impact on blood pressure and cardiovascular disease.

Sowers JR, Frohlich ED.

Med Clin North Am. 2004 Jan;88(1):63-82. Review.

PMID:
14871051
20.

Supplemental Content

Support Center